Vir Biotechnology, Inc. 8-K

What Happened

• Vir Biotechnology, Inc. announced in an 8-K that it completed a public offering of common stock. The offering closed on February 27, 2026, after an underwriting agreement dated February 25, 2026, and the underwriters exercised their option in full.
• In total Vir issued and sold 20,294,117 shares of common stock at $8.50 per share, resulting in approximately $172.5 million of gross proceeds before underwriting discounts, commissions and offering expenses.

Key Details

• Initial offering size: 17,647,059 shares at $8.50 per share.
• Overallotment: Underwriters had a 30-day option for up to 2,647,058 additional shares, which they exercised in full on February 26, 2026.
• Closing date: February 27, 2026.
• Underwriters (representatives): Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc.

Why It Matters

• The offering raises significant cash (~$172.5M gross) to support Vir’s operations, programs and balance sheet needs; this reduces near-term reliance on other financing sources.
• Issuing 20.29 million new shares increases the company’s outstanding share count, which dilutes existing shareholders’ ownership percentage (the filing lists gross proceeds before fees, not net proceeds).
• Investors should note the timing, size and price of the raise when evaluating Vir’s capital position and potential impact on the stock; fees and expenses will reduce net proceeds.